InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar)

Wang C, He L, Peng J, et al. Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy. J Immunother Cancer. 2024,12(8). doi: 10.1136/jitc-2024-009404

Rafiei A, Gualandi M, Yang CL, et al. IOS-1002, a Stabilized HLA-B57 Open Format, Exerts Potent Anti-Tumor Activity. Cancers (Basel). 2024,16(16). doi: 10.3390/cancers16162902

Myers Chen K, Grun D, Gautier B, et al. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor. Front Immunol. 2024,15:1380065. doi: 10.3389/fimmu.2024.1380065

Sun Y, Chen Y, Zhang X, et al. ADCY4 promotes brain metastasis in small cell lung cancer and is associated with energy metabolism. Heliyon. 2024,10(7):e28162. doi: 10.1016/j.heliyon.2024.e28162

Dong H, He X, Zhang L, et al. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024,5(4):601-624. doi: 10.1038/s43018-024-00736-x

Liang M, Sun Z, Chen X, et al. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells. J Exp Clin Cancer Res. 2023,42(1):275. doi: 10.1186/s13046-023-02862-3

Lee DH, Ahn H, Sim HI, et al. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity. J Exp Clin Cancer Res. 2023,42(1):272. doi: 10.1186/s13046-023-02840-9

Yu W, He J, Wang F, et al. NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway. Immunology. 2023,169(1):69-82. doi: 10.1111/imm.13611

Choi B, Lee JS, Kim SJ, et al. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Lett. 2020,478:56-69. doi: 10.1016/j.canlet.2020.02.042